The deficiency is easy to rectify with diet or supplementation.
Mental confusion can be a sign of vitamin B12 deficiency, research suggests.
People with a B12 deficiency can have problems with their memory and concentration.
Depression symptoms like low mood and low energy are also linked to the deficiency.
Low levels of vitamin B12 can even contribute to brain shrinkage, other studies have suggested.
Around one-in-eight people over 50 are low in vitamin B12 levels, recent research finds.
The rates of deficiency are even higher in those who are older.
Fortunately, these deficiencies are easy to rectify with diet or supplementation.
Good dietary sources of vitamin B12 include fish, poultry, eggs and low-fat milk.
Fortified breakfast cereals also contain vitamin B12.
People who may have difficulty getting enough vitamin B12 include vegetarians, older people and those with some digestive disorders, such as Crohn’s disease.
One study has found that high doses of B vitamins can help reduce the symptoms of schizophrenia.
Schizophrenia is one of the most serious types of mental illness.
It can cause delusions, hallucinations, confused thinking and dramatic changes in behaviour.
The study reviewed 18 different clinical trials, including 832 patients.
It found that high doses of B vitamins helped reduce the symptoms of schizophrenia.
The vitamins were particularly effective if used early on in treatment.
Dr Joseph Firth, the study’s lead author, said:
“Looking at all of the data from clinical trials of vitamin and mineral supplements for schizophrenia to date, we can see that B vitamins effectively improve outcomes for some patients.
This could be an important advance, given that new treatments for this condition are so desperately needed.”
Professor Jerome Sarris, study co-author, said:
“This builds on existing evidence of other food-derived supplements, such as certain amino-acids, been beneficial for people with schizophrenia.”
About the author
Psychologist, Jeremy Dean, PhD is the founder and author of PsyBlog. He holds a doctorate in psychology from University College London and two other advanced degrees in psychology.
He has been writing about scientific research on PsyBlog since 2004.
The study was published in the journal Psychological Medicine (Firth et al., 2017).
August 6, 2021 source: PsyBlog
Vitamin D Reduces the Need for Opioids in Palliative Cancer
Patients with vitamin D deficiency who received vitamin D supplements had a reduced need for pain relief and lower levels of fatigue in palliative cancer treatment, a randomized and placebo-controlled study by researchers at Karolinska Institutet shows. The study is published in the scientific journal Cancers.
Among patients with cancer in the palliative phase, vitamin D deficiency is common. Previous studies have shown that low levels of vitamin D in the blood may be associated with pain, sensitivity to infection, fatigue, depression, and lower self-rated quality of life.
A previous smaller study, which was not randomized or placebo-controlled, suggested that vitamin D supplementation could reduce opioid doses, reduce antibiotic use, and improve the quality of life in patients with advanced cancer.
244 cancer patients with palliative cancer, enrolled in ASIH, (advanced medical home care), took part in the current study in Stockholm during the years 2017-2020.
All study participants had a vitamin D deficiency at the start of the study. They received either 12 weeks of treatment with vitamin D at a relatively high dose (4000 IE/day) or a placebo.
The researchers then measured the change in opioid doses (as a measurement of pain) at 0, 4, 8, and 12 weeks after the start of the study.
“The results showed that vitamin D treatment was well tolerated and that the vitamin D-treated patients had a significantly slower increase in opioid doses than the placebo group during the study period. In addition, they experienced less cancer-related fatigue compared to the placebo group,” says Linda Björkhem-Bergman, senior physician at Stockholms Sjukhem and associate professor at the Department of Neurobiology, Healthcare Sciences, and Society, Karolinska Institutet.
On the other hand, there was no difference between the groups in terms of self-rated quality of life or antibiotic use.
“The effects were quite small, but statistically significant and may have clinical significance for patients with vitamin D deficiency who have cancer in the palliative phase. This is the first time it has been shown that vitamin D treatment for palliative cancer patients can have an effect on both opioid-sensitive pain and fatigue,” says first author of the study Maria Helde Frankling, senior physician at ASIH and postdoc at the Department of Neurobiology, Healthcare Science and Society, Karolinska Institutet.
The study is one of the largest drug studies conducted within ASIH in Sweden. One weakness of the study is the large drop-out rate. Only 150 out of 244 patients were able to complete the 12-week study because many patients died of their cancer during the study.
The study was funded by Region Stockholm (ALF), the Swedish Cancer Society, Stockholms Sjukhems Foundation and was carried out with the support of ASIH Stockholm Södra and ASIH Stockholm Norr.
Materials provided by Karolinska Institutet. Note: Content may be edited for style and length.
Maria Helde Frankling, Caritha Klasson, Carina Sandberg, Marie Nordström, Anna Warnqvist, Jenny Bergqvist, Peter Bergman, Linda Björkhem-Bergman. ‘Palliative-D’—Vitamin D Supplementation to Palliative Cancer Patients: A Double Blind, Randomized Placebo-Controlled Multicenter Trial. Cancers, 2021; 13 (15): 3707 DOI: 10.3390/cancers13153707